Author: The Lancet
Author Contact: thelancet.com
Published: 21st Oct 2022
Peer-Reviewed Publication: Yes
Additional References: Transgender News Publications
Summary: Study suggests 98% of adolescents with gender dysphoria who initiated gender-affirming hormone treatment as adolescents continued use at follow-up.
Gender dysphoria is a diagnosis that refers to people whose gender at the time of their birth is contrary to the one they identify with. It constitutes a new diagnostic class in the American Psychiatric Association's Diagnostic and Statistical Manual (DSM) of Mental Disorders, Fifth Edition. The diagnosis replaces the DSM-IV diagnosis of gender identity disorder. The DSM diagnostic criteria for gender dysphoria include intense and persistent cross-gender identification that extends beyond a desire for a perceived cultural advantage.
Continuation of Gender-Affirming Hormones in Transgender People Starting Puberty Suppression in Adolescence: A Cohort Study in The Netherlands
This is the most extensive study to date investigating the continuation of gender-affirming hormone treatment in those who initiated treatment as adolescents. Among individuals treated at a gender identity clinic in The Netherlands, those who used puberty suppressing treatment before the age of 18 and then started gender-affirming hormones, 98% (704 out of 720) continued use at follow-up, according to an observational study published in The Lancet Child & Adolescent Health journal.
Marianne van der Loos, MD at Amsterdam UMC, Vrije Universiteit Medical Center Amsterdam, The Netherlands, says,:
"Our study looked at individuals treated at a gender identity clinic in The Netherlands, which has offered puberty suppression treatment followed by gender-affirming hormones to transgender people for over 20 years, to understand how many people continued to use hormone therapy. We found that most people continued using gender-affirming hormones, reassuring in the context of recent increased public concern regarding regret of transitioning." [1]
In 1998, The Netherlands was the first country to introduce a new treatment protocol for young people diagnosed with gender dysphoria under 18. After a thorough diagnostic evaluation, adolescents are offered reversible puberty suppression treatment (using a gonadotropin-releasing hormone agonist). This pauses the physical changes associated with puberty that can be stressful for adolescents with gender dysphoria and gives them time to explore their gender identity. Those who continue to desire to transition medically can subsequently begin gender-affirming hormone treatment after age 15-16, which means taking medications (i.e., oestradiol or testosterone) to induce physical feminization or masculinization in a way that aligns with their gender identity.
However, puberty suppression and gender-affirming hormone treatment for people under 18 years old have recently become a subject of public debate. Some countries have taken legal measures to ban or limit its use, such as in the USA and UK. [2,3] Short-term studies have demonstrated the beneficial effects of puberty suppression treatment on adolescents' mental and physical health, but long-term follow-up data are lacking.
The study used medical records from a gender identity clinic in Amsterdam. Individuals were included if they used puberty-suppressing treatment before age 18 for a minimum of three months before using gender-affirming hormones. To investigate the proportion of these people who continued using treatment at follow-up, the study linked their records to the nationwide prescription registry to determine if individuals were still receiving a prescription for gender-affirming hormones at the end of data collection (December 2018). The follow-up periods varied by the patient, with the most recent patients having the shortest follow-up period. The authors stress that results from patients with shorter follow-up periods should be regarded with caution.
Included in the study were 720 people, of whom 31% (220) people were assigned male at birth (AMAB), and 69% (500) were assigned female at birth (AFAB). For AMAB people, the median age was 14 when starting puberty-suppressing treatment and 20 years old at the end of follow-up. For AFAB people, the median age was 16 when starting puberty blockers and 19 at the end of the follow-up.
Out of 720 individuals in the study, 704 continued using gender-affirming hormones until following up, amounting to 98% of individuals continuing hormone therapy.
Regarding the 2% (16 out of 720) of people no longer using gender-affirming hormones, it remains unknown whether they stopped using hormones because they regretted transitioning or changing their gender. The authors stress several plausible explanations, including a lack of knowledge on the importance of continuing hormone treatment after gonadectomy (surgical removal of either the testes or the ovaries) or participants with non-binary gender identity only wanting to use hormone treatment for a short period. The authors recommend that future research should identify reasons why a small number of people who initiate this treatment as adolescents subsequently stop taking gender-affirming hormones.
The study did not identify any factors associated with a higher chance of stopping gender-affirming hormone treatment. The individuals' age or the year when they first visited the clinic, when they started puberty-suppressing treatment when they started gender-affirming hormone treatment, and whether they had undergone a gonadectomy were not associated with discontinuation.
An increase in referrals of AFAB individuals to this gender identity clinic after 2012 had been documented, so whether discontinuation rates were different before this year compared to afterward was also investigated. The results suggest that there is no difference between continuation rates before 2012 compared to afterward.
The authors note several limitations of their study. Gender-affirming hormones being prescribed does not necessarily mean an individual is taking the medication as prescribed, potentially leading to an overestimation in the number of individuals continuing use. On the other hand, prescriptions might not have been recorded for anyone obtaining these medications outside the regular health system, potentially underestimating the number of individuals continuing use.
Discontinuation of Gender Affirming Hormones in Those Who Start Treatment Young is Rare | The Lancet (thelancet.com). SexualDiversity.org makes no warranties or representations in connection therewith. Content may have been edited for style, clarity or length.
Post to Twitter Add to Facebook
| Latest Transgender News Publications | |
|---|---|
The above information is from our reference library of resources relating to Transgender News that includes: | |
 | Peri-Operative Care of Transgender and Gender-Diverse Individuals New guidance for clinicians and departments published for peri-operative care of transgender and gender-diverse individuals. Publish Date: 24th Jul 2024 |
| Study Highlights Need for Tailored Prostate Cancer Screening Guidelines for Transgender Women Study finds PSA tests may give false reassurance for transgender women on estrogen therapy and could miss some cancers. Publish Date: 28th Jun 2024 |
| Dietary Supplement Use in Transmasculine People Study highlights the need for population-level research on the nutritional needs of transgender people. Publish Date: 25th Mar 2024 |
 | Transgender Scientists Address Academic Challenges and Offer Ways to Provide Support Transgender, and family members of transgender, scientists describe what it is like to be a transgender person in STEMM. Publish Date: 14th Mar 2024 - Updated: 5th Oct 2024 |
1Transgender Reporting Guide
How to write about transgender people.
2Am I Gay? Questions to Ask
Think you may be gay or bisexual?
3Glossary of Sexuality Terms
Definitions of sexual terms & acronyms.
4LGBTQ+ Pride Flags
Symbols of Identity and Inclusion.
5LGBT Awareness Dates
Important LGBTQ community awareness days, remembrance dates, and coming pride events.
• Submissions: Send us your coming events and LGBTQ related news stories.
• Report Errors: Please report outdated or inaccurate information to us.
• (APA): The Lancet. (2022, October 21). Discontinuation of Gender Affirming Hormones in Those Who Start Treatment Young is Rare. SexualDiversity.org. Retrieved October 13, 2024 from www.sexualdiversity.org/news/transgender/1043.php
• Permalink: <a href="https://www.sexualdiversity.org/news/transgender/1043.php">Discontinuation of Gender Affirming Hormones in Those Who Start Treatment Young is Rare</a>